Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297034 | 0.86 | KDM1A (0.51) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL19284642 | 0.85 | PDE4B (0.53) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL5454387 | 0.83 | GPR119 (0.57) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1774390 | 0.83 | KMT2A (0.41) | PDE4BKDM4E | |
| SCHEMBL19297022 | 0.81 | PDE4B (0.49) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3376953 | 0.81 | PDE4B (0.47) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL215918 | 0.81 | KDM1A (0.66) | KDM1APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1808004 | 0.81 | GPR119 (0.51) | KDM1AGPR119KDM4EPKM | |
| SCHEMBL4470775 | 0.81 | GPR119 (0.51) | KDM1AGPR119 | |
| SCHEMBL19297052 | 0.81 | CCR8 (0.54) | GPR119KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | KDM1A 2473/4885PDE4B 1973/4885PDE4D 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.